| Autor: |
Richard B. Lock, Malcolm A. Smith, Peter J. Houghton, Stephen P. Hunger, Mignon L. Loh, Cheryl L. Willman, Charles G. Mullighan, Catherine A. Billups, Raushan T. Kurmasheva, Kathryn G. Roberts, Philipp A. Dietrich, Kathryn Evans, I-Ming Chen, Hernan Carol, Keith C.S. Sia, Richard C. Harvey, Lauryn S. Bracken, Santi Suryani |
| Rok vydání: |
2023 |
| Popis: |
Supplementary Materials and Methods. Supplementary Table S1. QC of Affymetrix U133_Plus_2.0 Data. Supplementary Table S2. Summary of the Objective Response Measure (ORM) scoring methodology. Supplementary Table S3. Correlation of xenograft with parent U133_Plus_2.0 expression. Supplementary Table S4. Probe sets where parent expression is always greater than xenograft. Supplementary Table S5. Probe sets where xenograft expression is always greater than parent. Supplementary Table S6. Complete summary of in vivo AZD1480 single agent responses for individual mice. Supplementary Table S7. In vitro Combination Indices (CIs) for AZD1480 and selumetinib. Supplementary Table S8. In vivo responses of JAK-mutated ALL xenografts to AZD1480/selumetinib combination treatment. Supplementary Table S9. Complete summary of in vivo AZD1480 single agent and AZD1480/selumetinib combination responses for individual mice. Supplementary Figure S1. Chemical structures of (A) AZD1480 and (B) selumetinib. Supplementary Figure S2. Relationship between high CRLF2 expression and engraftment potential of the P9906 cohort. Supplementary Figure S3. Probe set expression by range. Supplementary Figure S4. Heatmap of microarray gene expression data corresponding to the qRT-PCR data shown in Figure 1. Supplementary Figure S5. In vitro cytotoxicity of AZD1480 against ALL xenograft cells. Supplementary Figure S6. In vivo efficacy of single agent AZD1480 against ALL xenografts. Supplementary Figure S7. Time of drug exposure affects synergistic interactions of AZD1480 and selumetinib against JAK-mutated ALL xenografts. Supplementary Figure S8. The extent of inhibition of the JAK/STAT and MAPK signaling pathways depends on the length of exposure to AZD1480/selumetinib. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
